Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis

Netherlands Journal of Medicine

Volumn 50, Issue 5, 1997, Pages 191-197

  DeFronzo, R A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antihypertensive therapy; Dyslipidaemia; Glucose clamp; Hypertension; Insulin resistance syndrome; NIDDM; Obesity

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK FACTOR; SYNDROME;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; OBESITY; RISK FACTORS;

EID: 0030938616     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(97)00012-0     Document Type: Article

References (14)

1. Assmann G, Schulte H. The prospective Cardiovascular Munster (PROCAM) Study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988;116:1713-1724.
2. Haffner SM, Fong D, Hazuda HP, et al. Hyperinsulinemia, upper body adiposity and cardiovascular risk factors in nondiabetics. Metabolism 1988;37:338-345.
3. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990;39:167-174.
4. Pyorala K, Savolainen E, Kaukola S, Hoopakoski J. Plasma insulin and coronary heart disease risk factor relationship to other risk factors and predictive value during 9 1/2 year follow up of the Helsinki Policemen Study population. Acta Med Scand 1985;701:38-52.
5. Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991;34:356-361.
6. Cullen K, Stenhouse NS, Wearne KL, Welborn JA. Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton. Western Australia - 13 year study. J Chronic Dis 1983;36:371-377.
7. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-957.
8. Yarnell JWG, Sweetman PM, Marks V, et al. Insulin in ischemic heart disease: are associations explained by concentrations? The Caerphilly prospective study. Br Heart J 1994;71:293-296.
9. Cruz AB, Amatuzio DS, Grande R, Hay L. Effect of intraarterial insulin on tissue cholesterol and fatty acids in alloxan-diabetic dogs. Circ Res 1961;9:39-43.
10. Collins R, Petro R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. II. Short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
11. Warram JH, Laffel LMP, Valsamia P, et al. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Int Med 1991;151:1350-1356.
12. Multiple Risk Factor Intervention Trials Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in Multiple Risk Factor Intervention Trial. Am J Cardiol 1985;55:1-15.
13. Klein R, Moss SE, Klein BEK, DeMets DL. Relation of ocular and systemic factors to survival in diabetes. Arch Intern Med 1989;149:266-272.
14. Bressler P, Bailey SR, Matsuda M, DeFronzo RA. Insulin resistance and coronary artery disease. Diabetologia 1996;39:1345-1350.